Emboline Receives U.S. Allowance for Key Piece of Its Seminal Patent Portfolio of Aortic Embolic Protection Technologies for Percutaneous Heart Valve Procedures Such as TAVR

Published: Nov 30, 2011

FREMONT, Calif.--(BUSINESS WIRE)--Emboline, Inc., an emerging medical device company, has received Notice of Allowance from the United States Patent and Trademark Office (USPTO) related to its aortic embolic protection devices for percutaneous heart valve repair and replacement. The Company is initially focused on developing its novel Emboline CAP™ device: a game-changing, next-generation system intended to provide complete protection of the arterial bed (both the cerebrals and the aortic lumen) utilizing a uniquely ported design that maintains tool access through the filter. In addition, Emboline is also developing Emboliner™, a simple-to-use system for protection of the cerebral vessels alone.

Back to news